NCT02579863 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 154
- group Id
- BG002
- value
- 310
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
- id
- BG000
- title
- Pembrolizumab + Lenalidomide + Dexamethasone
- description
- Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
- id
- BG001
- title
- Lenolidomide + Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.0
- value
- 74.4
- group Id
- BG001
- spread
- 5.9
- value
- 74.3
- group Id
- BG002
- spread
- 6.0
- value
- 74.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 166
- title
- Female
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 144
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 143
- group Id
- BG001
- value
- 136
- group Id
- BG002
- value
- 279
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 54
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 12
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 115
- group Id
- BG001
- value
- 121
- group Id
- BG002
- value
- 236
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 92
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 70
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 136
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 80
- title
- Stage III
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Missing
- description
- The International Staging System (ISS) defines the factors that influence patient survival. The system has 3 stages based on the measurement of serum albumin and the levels of serum β2-microglobulin (β2-M). Stage I: β2-M \<3.5 mg/L with a serum albumin of 3.5 g/dL or more; Stage II: Either of these 2 criteria: β2-M between 3.5 mg/L and 5.5 mg/dL Albumin \<3.5 g/dL; Stage III: β2-M \>5.5 mg/L.
- param Type
- NUMBER
- title
- International Stage (I, II, III).
- unit Of Measure
- Participants
- population Description
- The analysis population included all randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 156
- group Id
- BG001
- value
- 154
- group Id
- BG002
- value
- 310
- units
- Participants
- groups
- description
- Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
- id
- BG000
- title
- Pembrolizumab + Lenalidomide + Dexamethasone
- description
- Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
- id
- BG001
- title
- Lenolidomide + Dexamethasone
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.0
- value
- 74.4
- group Id
- BG001
- spread
- 5.9
- value
- 74.3
- group Id
- BG002
- spread
- 6.0
- value
- 74.3
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 85
- group Id
- BG001
- value
- 81
- group Id
- BG002
- value
- 166
- title
- Female
- measurements
- group Id
- BG000
- value
- 71
- group Id
- BG001
- value
- 73
- group Id
- BG002
- value
- 144
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 143
- group Id
- BG001
- value
- 136
- group Id
- BG002
- value
- 279
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 23
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 27
- group Id
- BG001
- value
- 27
- group Id
- BG002
- value
- 54
- title
- Asian
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 12
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 115
- group Id
- BG001
- value
- 121
- group Id
- BG002
- value
- 236
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 6
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 53
- group Id
- BG002
- value
- 92
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 70
- group Id
- BG001
- value
- 66
- group Id
- BG002
- value
- 136
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 80
- title
- Stage III
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Missing
- description
- The International Staging System (ISS) defines the factors that influence patient survival. The system has 3 stages based on the measurement of serum albumin and the levels of serum β2-microglobulin (β2-M). Stage I: β2-M \<3.5 mg/L with a serum albumin of 3.5 g/dL or more; Stage II: Either of these 2 criteria: β2-M between 3.5 mg/L and 5.5 mg/dL Albumin \<3.5 g/dL; Stage III: β2-M \>5.5 mg/L.
- param Type
- NUMBER
- title
- International Stage (I, II, III).
- unit Of Measure
- Participants
- population Description
- The analysis population included all randomized participants.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle